Genomic medicine is undergoing rapid change after the Japanese public health insurance system began to cover genetic testing in 2019. Cancer patients who meet certain criteria are able to take these tests for a relatively affordable price, and their genetic information is collected in a massive database and analyzed with the help of around 170 hospitals across the country. But challenges remain, with suitable drugs available for only 10% of patients who undergo testing.
Comments are closed.